The Jak2 V617F mouse polycythemia vera model is the most widely used preclinical platform for studying myeloproliferative neoplasms and evaluating targeted therapeutics such as JAK inhibitors. This article provides a comprehensive technical overview of model construction, experimental design, sample collection, testing items, analytical methods, and translational applications. By standardizing hematological, molecular, and histopathological endpoints, researchers can generate reproducible efficacy data that directly support drug development programs.
Technical Overview
Polycythemia vera (PV) is a Philadelphia chromosome-negative myeloproliferative neoplasm characterized by uncontrolled production of red blood cells, panmyelosis, splenomegaly, and a progressive risk of evolution toward myelofibrosis and acute leukemia. More than 95% of PV patients carry the somatic Jak2 V617F mutation, a guanine-to-thymine substitution in exon 14 that converts valine 617 to phenylalanine within the pseudokinase (JH2) domain of the Jak2 tyrosine kinase. This mutation disrupts the autoinhibitory interaction between the pseudokinase and kinase domains, resulting in constitutive Jak2 activation and persistent signaling through STAT5, STAT3, MAPK/ERK, and PI3K/AKT pathways in hematopoietic stem and progenitor cells.
The Jak2 V617F mouse model experiment recreates the core features of human PV in an immunocompetent murine system. Two dominant modeling strategies are routinely used:
- Bone marrow transplantation (BMT) model: donor marrow is harvested after 5-fluorouracil mobilization, transduced ex vivo with a retroviral vector expressing Jak2 V617F together with a GFP reporter, and transplanted into lethally irradiated syngeneic recipients. Marked erythrocytosis typically develops within two to four weeks post-transplantation.
- Genetic models: conditional knock-in mice carrying the Jak2 V617F allele activated via Mx1-Cre induction with polyinosinic-polycytidylic acid, or transgenic mice expressing human JAK2 V617F under hematopoietic promoters such as Vav1, develop a slower-onset, more chronic disease course.
Disease-bearing animals display hematocrit values frequently exceeding 60%, elevated hemoglobin and red blood cell counts, suppressed serum erythropoietin (EPO), massive splenomegaly with extramedullary hematopoiesis, endogenous erythroid colony growth independent of EPO, and late-stage bone marrow fibrosis. These phenotypes collectively validate the model as a faithful surrogate of human PV for pharmacological intervention studies.
Testing Samples
Peripheral Blood
Peripheral blood is collected at serial time points (typically days 14, 28, 42, and 56 post-modeling) from the tail vein, saphenous vein, or submandibular plexus into EDTA-coated tubes. Blood samples serve for complete blood counts, reticulocyte analysis, peripheral smears, genomic DNA extraction for mutant allele quantification, and flow cytometric assessment of circulating progenitor populations. Blood volumes must comply with institutional animal care guidelines, generally limited to less than 10% of total circulating volume per collection.
Bone Marrow
Bone marrow is harvested at terminal necropsy by flushing femurs, tibias, and pelvic bones with phosphate-buffered saline supplemented with 2% fetal bovine serum. Marrow cells are allocated to flow cytometry for hematopoietic stem and progenitor cell phenotyping, colony-forming cell assays in methylcellulose culture, genomic DNA isolation for allele burden measurement, and protein extraction for Western blot analysis of phosphorylated signaling intermediates.
Spleen and Liver Tissue
The spleen is weighed immediately upon retrieval, and the spleen-to-body weight ratio is calculated as a quantitative index of disease burden. Sections of spleen, liver, and lung are divided for formalin fixation and paraffin embedding, snap-freezing in liquid nitrogen for molecular assays, and single-cell suspension preparation for immunophenotyping. Histological evaluation documents extramedullary hematopoiesis, architecture distortion, and fibrotic progression.
Serum and Plasma
Serum is separated from clotted whole blood by centrifugation and stored at -80 degrees Celsius. Serum samples are used to quantify erythropoietin, inflammatory cytokines including IL-6, TNF-alpha, and G-CSF, as well as biochemical indicators of hepatic and renal function. Suppressed EPO is a hallmark confirming polycythemia driven by Jak2 V617F rather than secondary hypoxia-driven erythrocytosis.
Testing Items
Hematological Parameters
- Red blood cell count, hemoglobin concentration, and hematocrit, the primary efficacy endpoints
- White blood cell count with differential and neutrophil-to-lymphocyte ratio
- Platelet count and mean platelet volume
- Erythrocyte indices including MCV, MCH, MCHC, and red cell distribution width
- Reticulocyte percentage and absolute reticulocyte count
- Peripheral blood smear morphology including nucleated red cells and megakaryocyte fragments
Molecular and Genetic Markers
- Jak2 V617F mutant allele frequency in blood, marrow, and spleen genomic DNA
- Transgene or vector copy number in BMT models via GFP-linked quantification
- Expression of pathway target genes such as Pim1, SocS3, and Bcl-xL by quantitative PCR
- Phospho-STAT5, phospho-STAT3, and phospho-ERK levels in lineage-positive and progenitor compartments
Cellular and Immunophenotypic Analysis
- Erythroid maturation staging using CD71 and Ter119 markers
- Hematopoietic stem and progenitor quantification using the LSK (Lin-Sca1+c-Kit+) gate and downstream subsets
- Myeloid and megakaryocytic expansion markers including Gr-1, Mac-1, and CD41
- Serum erythropoietin concentration by enzyme-linked immunosorbent assay
Histopathological Evaluation
- Spleen and liver extramedullary hematopoiesis grading on hematoxylin and eosin sections
- Bone marrow cellularity and megakaryocyte clustering assessment
- Reticulin and Masson trichrome staining to stage myelofibrosis
- Blood vessel thrombi and tissue iron deposition surveys
Testing Methods
Complete Blood Count Analysis
Automated hematology analyzers calibrated for murine blood generate full CBC panels from 20 to 50 microliters of EDTA-anticoagulated blood. Manual smear review confirms analyzer flags and documents morphological abnormalities. Hematocrit elevation above 55% together with hemoglobin exceeding 18 g/dL in C57BL/6 backgrounds is generally accepted as successful disease establishment.
Allele-Specific Quantitative PCR and Droplet Digital PCR
Mutant allele burden is quantified using allele-specific TaqMan probes or droplet digital PCR partitioning, which achieves sensitivities below 0.1% variant fraction. Serial monitoring of allele burden provides a pharmacodynamic readout of disease-modifying activity, distinguishing cytoreductive agents from truly clone-suppressive therapies.
Flow Cytometry and Phospho-Flow Cytometry
Multiparameter flow cytometry on a multicolor analyzer enables simultaneous enumeration of stem, progenitor, and mature lineage compartments from marrow and spleen single-cell suspensions. Phospho-flow protocols with fixation and permeabilization measure intracellular phospho-STAT5 responses to cytokine stimulation or inhibitor treatment at the single-cell level, providing high-resolution target engagement data.
ELISA and Multiplex Cytokine Profiling
Sandwich ELISA quantifies serum erythropoietin, while multiplex bead-based panels measure inflammatory cytokines elevated in the myeloproliferative syndrome. Reduction of proinflammatory mediators is a clinically translatable endpoint given that constitutional symptoms in PV patients correlate with cytokine burden.
Colony-Forming Cell Assays
Marrow and spleen cells are plated in methylcellulose media with and without recombinant erythropoietin. Formation of erythroid colonies in the absence of EPO, the hallmark endogenous erythroid colony phenotype, is enumerated at days 7 to 14 and represents a functional assay of cytokine-independent signaling downstream of Jak2 V617F.
Histology and Reticulin Fiber Staining
Fixed tissues are processed to paraffin blocks, sectioned at 4 micrometers, and stained with hematoxylin and eosin for architecture, Gordon-Sweets reticulin for fiber density, and trichrome for collagen deposition. Blinded scoring by a veterinary pathologist using standardized myelofibrosis grading scales supports objective comparison between treatment arms.
Applications
The Jak2 V617F mouse polycythemia vera model experiment serves as a decisive translational bridge for multiple research and development objectives:
- Efficacy evaluation of JAK inhibitors including ruxolitinib, fedratinib, and pacritinib on hematocrit, spleen volume, cytokine burden, and survival
- Assessment of next-generation agents such as type-I JAK2 inhibitors, HIF-2alpha inhibitors, hepcidin agonists, and PI3K/mTOR pathway blockers
- Mechanistic dissection of constitutive erythropoiesis, altered iron metabolism, and inflammatory signaling driven by the V617F kinase
- Study of disease progression from polycythemia to myelofibrosis and clonal evolution toward acute myeloid leukemia
- Biomarker discovery and validation including allele burden, phospho-STAT5 signatures, and circulating cytokine panels
- Combination therapy design exploring schedule, sequencing, and resistance mitigation strategies
- Support of IND-enabling packages requiring in vivo proof-of-concept data in a clinically relevant genetic model
FAQ
How long does it take for the Jak2 V617F model to develop a polycythemia phenotype?
In the retroviral bone marrow transplantation model, significant erythrocytosis is typically observed within 14 to 28 days post-transplantation, with hematocrit values plateauing above 60% by week four. Genetic knock-in and transgenic models develop disease more gradually, often requiring eight to sixteen weeks after Cre-mediated induction, but reproduce a more chronic disease trajectory with authentic progression to fibrosis.
What criteria confirm successful model establishment?
Successful modeling is confirmed by a composite of hematocrit elevation above 55% in conjunction with increased hemoglobin and red cell mass, suppressed serum erythropoietin, splenomegaly with a spleen-to-body weight ratio at least threefold above controls, and detection of the Jak2 V617F allele in hematopoietic tissues. Endogenous erythroid colony formation provides strong functional confirmation.
Which mouse strain is preferred for this experiment?
C57BL/6 mice are the most commonly used background because the retroviral BMT model requires syngeneic donors and recipients, and because the majority of immunological reagents are validated on this strain. BALB/c and FVB strains have also been used successfully, though baseline hematological values differ and historical controls must be strain-matched.
Does the model recapitulate progression to myelofibrosis?
Yes. In the BMT model, reticulin fibrosis in the marrow and spleen emerges approximately 8 to 12 weeks after transplantation, while knock-in models develop fibrosis over several months accompanied by megakaryocytic hyperplasia and osteosclerosis. Late time-point studies should incorporate reticulin and trichrome staining to capture fibrotic progression.
What controls should be included in a pharmacology study using this model?
A well-designed study includes a vehicle-treated disease group, a wild-type transplantation or littermate control group, and a positive control arm using a benchmark JAK inhibitor such as ruxolitinib. Randomization based on baseline hematocrit, blinded endpoint assessment, and prespecified primary endpoints strengthen data integrity and regulatory acceptability.
Can the model be used to measure mutant allele burden as a disease-modifying endpoint?
Absolutely. Serial quantification of the Jak2 V617F mutant allele fraction by droplet digital PCR in peripheral blood provides a minimally invasive pharmacodynamic marker. Agents that reduce allele burden demonstrate clone-directed activity beyond symptom control, a distinction of major importance in myeloproliferative neoplasm drug development.